Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.

Abstract

AIM:

This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma.

METHODS:

From Nov 1999 to Jan 2002, 291 consecutive patients with stage IB-IIIB gastric adenocarcinoma were given FAM adjuvant chemotherapy. Chemotherapy comprised intravenous 5-FU 600 mg/m(2) (days 1, 8, 29 and 36), doxorubicin 30 mg/m(2) (days 1 and 29) and mitomycin-C 10 mg/m(2) (day 1), every 8 weeks for 6 months.

RESULTS:

The median follow-up time was 60.6 months, 92 patients died, and 93 patients had recurrent disease. The 5-year overall survival (OS) rates were 85.9% for stage IB, 72.1% for stage II, 58.0% for stage IIIA, and 48.2% for stage IIIB (p=0.002). The 5-year relapse-free survival (RFS) rates were 85.2% for stage IB, 71.2% for stage II, 53.3% for stage IIIA, and 39.2% for stage IIIB (p<0.001). A total of 769 cycles of chemotherapy were delivered, and 15 patients experienced grade 3 or higher leukopenia. The most common grade 3 or higher non-hematologic toxicity was nausea/vomiting (11 patients), followed by stomatitis (3 patients).

CONCLUSIONS:

Adjuvant chemotherapy with FAM for 6 months for gastric carcinoma indicated comparable RFS and OS with an acceptable toxicity profile.

• Authors: D H Koo, J L Lee, T W Kim, H M Chang, M H Ryu, J H Yook, S T Oh, B S Kim, J S Lee, Y K Kang
• Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Eur J Surg Oncol) Vol. 33 Issue 7 Pg. 843-8 (Sep 2007) ISSN: 0748-7983 [Print] England
• PMID: 17207959 (Publication Type: Journal Article)

Chemical References

• Mitomycin
• Doxorubicin
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy, mortality, surgery)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Disease-Free Survival
• Doxorubicin (administration & dosage, therapeutic use)
• Female
• Fluorouracil (administration & dosage, therapeutic use)
• Follow-Up Studies
• Gastrectomy (methods)
• Humans
• Incidence
• Korea (epidemiology)
• Male
• Middle Aged
• Mitomycin (administration & dosage, therapeutic use)
• Neoplasm Recurrence, Local (epidemiology)
• Neoplasm Staging
• Retrospective Studies
• Stomach Neoplasms (drug therapy, mortality, surgery)
• Survival Rate (trends)
• Time Factors
• Treatment Outcome